Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis - sprookjes - yvandenbroek - TriplyDB

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis

http://www.wikidata.org/entity/Q33804860

about

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis

http://www.wikidata.org/entity/Q33804860

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Fracture Preventing Effects of ...... in Patients with Osteoporosis

@ast

Fracture Preventing Effects of ...... in Patients with Osteoporosis

@en

type

label

Fracture Preventing Effects of ...... in Patients with Osteoporosis

@ast

Fracture Preventing Effects of ...... in Patients with Osteoporosis

@en

prefLabel

Fracture Preventing Effects of ...... in Patients with Osteoporosis

@ast

Fracture Preventing Effects of ...... in Patients with Osteoporosis

@en

P1433

Q33804860-E2D28AF7-2988-41D5-9648-46F9D9860F42

P1476

Q33804860-DFB56986-84C6-4C36-9C1F-2E1AFA7D5740

P2093

Q33804860-13A58616-55CC-4269-982C-6EAE66B89438

Q33804860-361ECD86-1891-4B91-B99C-00C218DD0609

Q33804860-488983C2-C82E-4E11-A31B-3D25675877FB

Q33804860-651FE268-17F1-4422-B6B9-DF6D987BE641

Q33804860-C6F5AAEA-2E18-49D6-84CF-5F8DB7C9854D

Q33804860-DEF993DB-3180-4DE9-9035-AECE89EB843C

P2860

Q33804860-05FEEAD5-E72C-4948-9A30-3F832473D016

Q33804860-09AD2E30-419F-4960-88F1-CC8F1D87A32B

Q33804860-1B73D986-99AE-497E-BAA3-C15402E04A4C

Q33804860-3A66553F-7CB4-476F-B2AC-3FD2D63AD1E6

Q33804860-41F6E3FE-743B-4DC6-9007-3F4D2D5B261E

Q33804860-4C35A903-655A-4567-A51E-56F2BAD97847

Q33804860-5E417188-928F-41F5-8827-BC916266D231

Q33804860-66A5E1EF-B58E-4431-AB47-ADBD57A11E39

Q33804860-7C0562EF-9AEF-47B6-BEDA-5DCEFD4EAF38

Q33804860-8F255ED6-7DB3-43A7-8706-7B47B7652EFC

P304

Q33804860-630D6D39-F226-4B92-9268-275391E00A63

P31

Q33804860-594309A9-6A19-4333-91CF-18DA8721AF60

P356

Q33804860-07F2A4C5-3E9F-4162-93E0-46B2298E3EB0

P433

Q33804860-449D04A5-4437-4862-AFD6-F7CA2F2556AC

P478

Q33804860-63DCDA96-C004-4639-A025-0CFE52617448

P50

Q33804860-0A6FA883-6F9F-45CB-B582-9F269BA155EE

P577

Q33804860-E3260FCB-576A-48EF-8D45-AEE068524E32

P698

Q33804860-BC4B9C14-E501-4774-AFB0-67935E694D72

P921

Q33804860-72D4C814-76BB-40F9-86E3-8C3CC558778F

P932

Q33804860-A79C9D62-118F-4A55-9649-B54D3595F317

P356

JBM.2017.24.2.91

P1433

Journal of bone metabolism : JBM

P1476

Fracture Preventing Effects of ...... in Patients with Osteoporosis

@en

P2093

Dong-Soo Kim

http://www.w3.org/2001/XMLSchema#string

Ju-Hyung Yoo

http://www.w3.org/2001/XMLSchema#string

Jun-Il Yoo

http://www.w3.org/2001/XMLSchema#string

Sang-Bum Kim

http://www.w3.org/2001/XMLSchema#string

Ye-Yeon Won

http://www.w3.org/2001/XMLSchema#string

Yong-Chan Ha

http://www.w3.org/2001/XMLSchema#string

P2860

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis

Current trends and future projections of hip fracture in South Korea using nationwide claims data.

Quality of life measurements in patients with osteoporosis and fractures.

Fractures in women treated with raloxifene or alendronate: a retrospective database analysis

Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.

Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS).

Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.

The efficacy and safety of a combined alendronate and calcitriol agent (maxmarvil): a postmarketing surveillance study in korean postmenopausal women with osteoporosis.

P304

91-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.11005/JBM.2017.24.2.91

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28642852

http://www.w3.org/2001/XMLSchema#string

P921

P932

5472803

http://www.w3.org/2001/XMLSchema#string